Medical Xpress - Cardiology
NOVEMBER 27, 2024
An irregular sleep-wake cycle is associated with a heightened risk of major cardiovascular events, such as heart attack and stroke, even for those who clock up the recommended nightly hours of shut-eye, finds research published online in the Journal of Epidemiology & Community Health.
Med Page Today
NOVEMBER 27, 2024
(MedPage Today) -- The relationship between air pollution and cardiovascular harm was supported by another study, this time down to the level of specific types of pollution that appeared to have varying effects according to geographical region.
Medical Xpress - Cardiology
NOVEMBER 27, 2024
Men with cardiovascular disease risk factors, including obesity, face brain health decline a decade earlier—from their mid 50s to mid 70s—than similarly affected women who are most susceptible from their mid 60s to mid 70s, suggest the findings of a long term study, published online in the Journal of Neurology Neurosurgery & Psychiatry.
Dr. Smith's ECG Blog
NOVEMBER 27, 2024
Pendell and I and the geniuses at Powerful Medical (Producers of the PMCardio Queen of Hearts OMI AI app ) are working on an objective, mathematical definition of hyperacute T-waves , based on real OMI outcomes and hyperacute T-wave annotation that has excellent interrater agreement (between me and Pendell), and it will end up being a logistic regression using these 3 variables: 1) area under the curve (AUC) relative to the QRS size 2) increased symmetry , as defined by time from T-wave onset to
Becker's Hospital Review - Cardiology
NOVEMBER 27, 2024
A recent study using data from the UK BioBank highlighted the extended risk of major adverse cardiac events in individuals who have recovered from COVID-19.
Medical Xpress - Cardiology
NOVEMBER 27, 2024
Certain hormone replacement therapy (HRT) tablets containing both estrogen and progestogen are associated with a higher risk of heart disease and rare but serious blood clots known as venous thromboembolism (VTE) in women around the age of menopause, finds a study from Sweden published in The BMJ today.
Science Daily - Heart Disease
NOVEMBER 27, 2024
Researchers have analysed the effects of seven different hormone treatments for menopausal symptoms on the risk of blood clots, stroke and heart attack. The study, which involved around one million women aged between 50 and 58, is the largest and most comprehensive study of currently prescribed hormonal substances in the world. The results show that the risks differ depending on the active substance and how the medicine is taken.
Cardiovascular Update brings together the best content for cardiovascular medicine professionals from the widest variety of industry thought leaders.
HeartRhythm
NOVEMBER 27, 2024
Although he is widely believed to have stated “and still it moves,” there is no documentary evidence that Galileo Galilei uttered these words subsequent to his forced retraction of his notion that the earth moved round the sun. His alleged statement, nonetheless, stated an obvious fact, which was eventually supported by evidence. Nowadays, we allegedly practice evidence-based medicine.
Medical Xpress - Cardiology
NOVEMBER 27, 2024
The rate of deaths from ischemic heart disease related to obesity nearly tripled in the U.S. over a two-decade span, according to new research. The rate for men more than tripled.
HCPLive
NOVEMBER 27, 2024
In this analysis, egg consumption among pregnant mothers was found to be insufficient for the development of oral tolerance to eggs among infants at 1 year of age.
Medical Xpress - Cardiology
NOVEMBER 27, 2024
Congenital heart defects are the most common form of human birth defect, but we still don't fully understand what causes them. Previous research had suggested that some heart defects could be triggered by problems with the placenta, the organ that provides oxygen and nutrients to the developing embryo.
HCPLive
NOVEMBER 27, 2024
These findings indicate that incorporating educational video materials for psoriasis improved engagement in the shared decision-making process.
Open Heart
NOVEMBER 27, 2024
The optimal timing for initiating direct oral anticoagulants (DOACs) for secondary stroke prevention in patients with atrial fibrillation and acute ischaemic stroke remains controversial due to concerns about haemorrhagic transformation. This study aimed to analyse the efficacy and safety of early versus late DOAC initiation. Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, a systematic review was conducted, searching major databases (PubMed, Embase, C
Dr. Paddy Barrett
NOVEMBER 27, 2024
The Heart Health Formula is the process I use to: Understand a person’s risk of heart disease using the best science available. Maximally reduce a person’s risk. With the ultimate goal that all of my patients (Myself included) live a long and healthy life and die with, not from, heart disease. The steps to implementing this process result from over a decade of research.
Open Heart
NOVEMBER 27, 2024
Introduction Atrial fibrillation (AF)-induced cardiomyopathy (AIC) is retrospectively defined after normalisation of left ventricular ejection fraction (LVEF) in sinus rhythm. It is unclear why some patients develop AIC. Hypothesis Patients with AIC have a subtle cardiomyopathic process that precedes their AF-mediated LVEF reduction. Detailed assessment of cardiac function after successful catheter ablation will reveal this.
All About Cardiovascular System and Disorders
NOVEMBER 27, 2024
Though echocardiography is the sheet anchor of diagnosis of hypertrophic cardiomyopathy, clinical evaluation is equally important while deciding management and ruling out differential diagnoses. Role of cardiac cath is now mostly limited to septal ablation. Magnetic resonance imaging and bone scan to rule out transthyretin amyloidosis may be considered when clinically indicated.
Open Heart
NOVEMBER 27, 2024
Introduction Cardiac implantable electronic devices (CIED) can transfer data to the healthcare team, remotely. National and international cardiac organisations recommend all patients use this technology, however patient engagement is suboptimal. Previously, in cardiovascular patients, SMS messaging services have shown improvements in patient engagement and subsequent health outcomes.
CardiacWire
NOVEMBER 27, 2024
Stunning topline results from Merck Winrevair’s Phase 3 ZENITH trial found that the drug significantly reduced morbidity and mortality risks in patients with pulmonary arterial hypertension, paving the way for stronger commercialization and further functional trials. PAH is a rare, progressive disease that increases blood pressure in the lungs, forcing the heart to pump harder.
HCPLive
NOVEMBER 27, 2024
Panelists discuss how cardiovascular disease remains a leading health concern in the United States, examining its rising prevalence, risk factors such as dyslipidemia, and management strategies aligned with AHA guidelines to reduce patient mortality.
Med Page Today
NOVEMBER 27, 2024
(MedPage Today) -- MedPage Today spoke with experts during an Instagram Live 2 years ago about the growing buzz around GLP-1 receptor agonists and their role in transforming diabetes and obesity care. Since then, the use of medications like semaglutide.
HCPLive
NOVEMBER 27, 2024
Panelists discuss how effective management of dyslipidemia through adherence to AHA guidelines is crucial for reducing cardiovascular mortality rates and improving patient outcomes.
HeartRhythm
NOVEMBER 27, 2024
The ventricular conduction system (VCS) is essential for highly synchronous myocardial excitation and contraction. Developmental and acquired diseases affecting VCS structure and function are responsible for a substantial burden of rhythm disturbances. We highlight 5 recently published studies that advance our understanding of VCS formation, function, pathophysiology, and therapeutics.
HCPLive
NOVEMBER 27, 2024
Panelists discuss how familial chylomicronemia syndrome (FCS) and persistent chylomicronemia are diagnosed either genetically or clinically, outlining the prevalence and disease burden of FCS in the US, as well as its signs, symptoms, and diagnostic criteria, and how to differentiate FCS from other forms of hyperlipidemia.
HeartRhythm
NOVEMBER 27, 2024
Endomyocardial biopsy (EMB) remains the reference method for diagnosing a range of cardiac conditions. Owing to its invasive nature, the risk of complications may be as high as 3%. Therefore, EMB tends to be performed when non-invasive methods are unable to reach a definitive diagnosis, guide clinical management or when histology is necessary. In such patients, the “last-resort” use of EMB may also incur diagnostic delay.
HCPLive
NOVEMBER 27, 2024
Panelists discuss how Familial Chylomicronemia Syndrome (FCS) fits into the context of severe hypertriglyceridemia, highlighting its distinct characteristics and the associated risks of acute pancreatitis.
HeartRhythm
NOVEMBER 27, 2024
Despite an elevated risk of sudden cardiac death among dialysis patients, implantable cardioverter defibrillators (ICDs) have not been shown to improve mortality and are associated with high complication rates. Subcutaneous (S-)ICDs may reduce the risk of complications for eligible dialysis patients, but safety and benefits versus transvenous (TV-)ICDs are unknown.
HCPLive
NOVEMBER 27, 2024
The panel of experts outline the primary treatment goals for patients with primary biliary cholangitis (PBC), detailing how goals adjust based on disease severity, the role of ursodeoxycholic acid (UDCA) as first-line therapy, and the challenges that may require therapy modifications based on biochemical response.
HeartRhythm
NOVEMBER 27, 2024
Technical success left bundle branch area pacing (LBBAP) is predicated upon deep septal penetration to capture left ventricular (LV) conduction system. Potential barriers include non-complaint interventricular septum (IVS) either due to fibrosis/scar, hypertrophy, or abnormal geometry in structurally abnormal/dilated hearts. Lead entanglement also hinders septal penetration, increases procedural/fluoroscopic times, necessitates repositioning, and usage of more hardware.
HCPLive
NOVEMBER 27, 2024
The panel of experts cover second-line treatment options for primary biliary cholangitis (PBC), focusing on the use of obeticholic acid (OCA), its mechanism of action, management of adverse effects like pruritus and fatigue, the role of off-label fibrates, and strategies for assessing and adjusting therapy based on patient response and adverse effects.
American College of Cardiology
NOVEMBER 27, 2024
What is the association between changes in maximum daily atrial fibrillation duration (MDAFD) and stroke or mortality in patients with cardiac implantable electronic devices (CIEDs)?
HCPLive
NOVEMBER 27, 2024
Fromme describes the importance of risk stratification in AATD and explains the potential utility of noninvasive fibrosis measures for predicting outcomes.
American College of Cardiology
NOVEMBER 27, 2024
The goal of the pCAD-POAF trial was to determine the efficacy and safety of partial cardiac denervation to reduce the risk of postoperative atrial fibrillation (POAF) following coronary artery bypass grafting (CABG).
HCPLive
NOVEMBER 27, 2024
David G. Armstrong, DPM, PhD, and Michael S. Conte, MD discuss Phase 2 results on anatomically directed lower extremity gene therapy for ulcer healing.
American College of Cardiology
NOVEMBER 27, 2024
The goal of the Amulet IDE trial was to evaluate left atrial appendage (LAA) occlusion with the Amulet device compared with the Watchman device among patients with nonvalvular atrial fibrillation (AF).
HCPLive
NOVEMBER 27, 2024
ONS-5010 missed the pre-specified non-inferiority endpoint set with the FDA, but Outlook Therapeutics plans to resubmit the BLA in Q1 of 2025.
The American Journal of Cardiology
NOVEMBER 27, 2024
Publication date: Available online 26 November 2024 Source: The American Journal of Cardiology Author(s): Luca Fazzini, Matteo Casula, Riccardo Cau, Marta Figueiral, Matteo Castrichini, Giulio Binaghi, Marco Corda, Naveen L.
HCPLive
NOVEMBER 27, 2024
Stone discussed the phase 3 MITIGATE study, other potential treatment strategies, and top research priorities moving forward for IgG4.
Expert insights. Personalized for you.
131 
Let's personalize your content